Fredericksen Interviewed About Potential Impact of Midterm Election on Mueller Probe
11 August 2018
Partner Scott Fredericksen was interviewed on CNN about the possible effect of the midterm election on the course of special counsel Robert Mueller’s investigation into Russian interference in the 2016 presidential election.
Fredericksen said the so-called Holder memo, which directs prosecutors not to take any action that could directly affect the political process, does not require Mueller to stop work on his investigation, though it probably would preclude him from issuing a report on his findings during the period between Labor Day and the Nov. 6 election.
“Mueller is not going to take any action for which he could be accused of throwing the election to the Democrats or the Republicans,” he said.
Fredericksen said the so-called Holder memo, which directs prosecutors not to take any action that could directly affect the political process, does not require Mueller to stop work on his investigation, though it probably would preclude him from issuing a report on his findings during the period between Labor Day and the Nov. 6 election.
“Mueller is not going to take any action for which he could be accused of throwing the election to the Democrats or the Republicans,” he said.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”